CTLA4 and melanoma: The CTLA-4 inhibitor is called ipilimumab, and PD-1 inhibitors include nivolumab and pembrolizumab, which are often used in melanoma therapies and can be used synergistically, as CTLA-4 mainly suppresses immune response in lymph nodes, whereas PD-1 does so in peripheral tissues [84].